Cizzle Biotechnology Holdings plc (LSE: CIZ) is developing a blood test to help in the early detection of lung cancer. The Company was spun out from the University of York, in 2006, around the work of Professor Coverley and colleagues and was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021. Cizzle Biotech was initially funded by Yorkshire Cancer Research, White Rose Technology Seed Corn Fund, Finance Yorkshire Seedcorn LLP and Viking Members, who with management, invested in the project to support the development of a prototype blood test. Its test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. Normal CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant has been shown to be highly correlated with early-stage lung cancer.